title: [Pneumococcal vaccination for prevention of pneumonia].
abstract: Aging of the immune system, so-called immunosenescence, is well documented as the cause of increased infection rates and severe, often complicated courses of infections in older adults. This is particularly true for pneumococcal pneumonia in older adults; therefore, the standing committee on vaccination of the Robert Koch Institute (STIKO) recommends a once only vaccination with 23-valent pneumococcal polysaccharide vaccine for all persons aged 60 years and over. Furthermore, the 13-valent pneumococcal conjugate vaccine is also available for administration in adults and is recommended by the STIKO for particular indications. The advantage of the pneumococcal conjugate vaccine is the additional induction of a T-cell dependent immune response that leads to good immunogenicity despite immunosenescence. Initial data from a recent randomized controlled trial, so far only presented at conferences, confirm that the conjugate vaccine also provides protection against non-bacteremic pneumococcal pneumonia, which is not provided by the polysaccharide vaccine. Thus, there are two vaccines for prevention of pneumococcal diseases: one with a broader range of serotype coverage but with an uncertain protection against non-bacteremic pneumococcal pneumonia and another one with less serotype coverage but more effective protection. Vaccination of children with the conjugate vaccine also leads to a rapid decrease of infections by the 13 vaccine serotypes even in adults because of herd protection effects. For prevention of pneumonia in older adults the additional benefit of a concurrent application of influenza vaccine and pneumococcal vaccine should be considered.
authors: Klinik für Geriatrie, Universitätsklinikum Jena, Bachstr. 18, 07743, Jena, Deutschland. anja.kwetkat@med.uni-jena.de.
authors: A
authors: A
authors: Kwetkat
authors: Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Deutschland.
authors: S
authors: S
authors: Hagel
authors: Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Deutschland.|Universitätsklinik für Innere Medizin I, Klin. Abt. f. Infektionen und Tropenmedizin, Medizinische Universität Wien, Wien, Österreich.
authors: C
authors: C
authors: Forstner
authors: Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Deutschland.
authors: M W
authors: MW
authors: Pletz
mesh_terms: D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000145:classification*; D011018:Pneumonia, Pneumococcal / Q000175:diagnosis* / Q000517:prevention & control*; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000008:administration & dosage
chemical_list: C538862:13-valent pneumococcal vaccine; C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
keywords: Aging/immunology; Pneumococcal conjugated vaccine; Pneumococcal polysaccharide vaccine; Recommendations, health planning; STIKO